Abstract 2788
Background
Deep learning (DL) is one of the best approaches to predict nonlinear behaviors from high dimensional data. Nevertheless predicting the outcome of patients affected by cancers from transcriptomic data has shown limited performance, even with DL (C-index usually <0.65). Transfer learning is a DL two-step method where a model is pre-trained for a basic task on large amount of data, and then fine-tuned on the aimed task. We hypothesized that using TL with RNAseq may improve the performances of cancer patients’ outcome estimation.
Methods
The model was a Multi-Mayer Perceptron (MLP) with 22913 inputs corresponding to genes bulk tumor whole genome RNAseq expression analysis. An important restriction was applied to the number of units at second layer (N = 100), with further linear decrease across subsequent layers. Architecture of the model (number of layers, skip connections), L1 normalization value and learning rate were optimized by grid search on 30 parallel models. Training was performed using Keras package in R. Data were split into 70% training, 15% cross validation, 15% validation for each step, without contamination between the 2 transfer learning steps. The pre-training step consisted in predicting the organs of sample origin using 17.487 public RNAseq data of normal & cancer tissues (GTEX from gtexportal.org & TCGA from cBioportal.org). Fine-tuning on patients survival used 6401 training tumors. The model’s performance on survival prediction was evaluated by C-index and the area under the survival receiver-operating characteristic curve (AUROC).
Results
The pre-training using GTEx and TCGA reached very high performance with validation accuracy of 0.96 to predict organ of origins for the best model (all models had validation accuracy > 0.9). Fine-tuning on survival, the prognostic performance of the best model on the validation cohort was C-index=0.74 and AUROC= 0.81 (80% of models had a C-index > 0.6). The best model had 8 hidden layers and a small penalization value.
Conclusions
Thanks to this original transfer learning method, we achieved a high performance to estimate cancer patients’ prognostic from whole genome expression, a classically challenging task. Learning on public databases is a valuable method of DL for personalized cancer care.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Angevin: Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: BeiGene; Advisory / Consultancy: BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: DebioPharma; Advisory / Consultancy: Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Janssen; Advisory / Consultancy: Lilly; Advisory / Consultancy: MedImmune; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Orion. A. Hollebecque: Advisory / Consultancy: Amgen; Advisory / Consultancy: Spectrum Pharmaceuticals; Advisory / Consultancy: Lilly; Advisory / Consultancy: Debiopharm; Travel / Accommodation / Expenses: Servier; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Lilly; Travel / Accommodation / Expenses: Incyte; Travel / Accommodation / Expenses: Debiopharm. E. Deutsch: Advisory / Consultancy: Boehringer; Advisory / Consultancy: Medimune; Advisory / Consultancy: Amgen; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): biotrachea; Research grant / Funding (institution): BristolMyersSquidd; Research grant / Funding (self): Clevelex; Research grant / Funding (self): EDF; Research grant / Funding (self): Lilly; Research grant / Funding (self): GlaxoSmisthKline; Research grant / Funding (self): Merk; Research grant / Funding (self): Nanobiotix; Research grant / Funding (self): Oseo; Research grant / Funding (self): Ray Search Laboratory; Research grant / Funding (self): Roche; Research grant / Funding (self): Ipsen; Research grant / Funding (self): Servier; Research grant / Funding (self): Takeda. C. Massard: Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: BeiGene; Advisory / Consultancy: BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: DebioPharma; Advisory / Consultancy: Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Janssen; Advisory / Consultancy: Lilly; Advisory / Consultancy: MedImmune; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Orion. L. Verlingue: Research grant / Funding (self): Bristol-Myers Squibb; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Adaptherapy. All other authors have declared no conflicts of interest.
Resources from the same session
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract